Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has analysts on the Bullish side this week.

June 16, 2018 - By Adrian Mccoy

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 8 analysts covering Sucampo Pharmaceuticals (NASDAQ:SCMP), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. Sucampo Pharmaceuticals had 9 analyst reports since December 18, 2017 according to SRatingsIntel. The firm has “Hold” rating given on Friday, January 5 by UBS. Leerink Swann downgraded Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Tuesday, January 2 to “Market Perform” rating. The rating was downgraded by B. Riley & Co on Tuesday, December 26 to “Neutral”. The stock has “Hold” rating by Mizuho on Wednesday, January 3. The stock has “Hold” rating by Maxim Group on Tuesday, December 26. The firm has “Hold” rating by FBR Capital given on Tuesday, December 26. On Friday, January 26 the stock rating was downgraded by Nomura to “Neutral”. Below is a list of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) latest ratings and price target changes.

26/01/2018 Broker: Nomura Old Rating: Buy New Rating: Neutral Old Target: $43 Downgrade
05/01/2018 Broker: UBS Rating: Hold New Target: $18.0 Downgrade
03/01/2018 Broker: Mizuho Rating: Hold New Target: $18.0 Maintain
02/01/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Old Target: $15 Downgrade
26/12/2017 Broker: FBR Capital Rating: Hold New Target: $18.0 Downgrade
26/12/2017 Broker: B. Riley & Co Old Rating: Buy New Rating: Neutral Old Target: $14 Downgrade
26/12/2017 Broker: Maxim Group Rating: Hold Downgrade
19/12/2017 Broker: Instinet Rating: Buy New Target: $43 Initiates Coverage On
18/12/2017 Broker: Nomura Rating: Buy New Target: $43 Initiates Coverage On

It closed at $18 lastly. It is up 0.00% since June 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $. The companyÂ’s marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: